Anti-PAI1 Anticorpo (A84079)

Name: Anti-PAI1 Antibody
Brand: Antibodies.com
SKU: A84079
Price: 480.0 USD
Availability: InStock

Questo prodotto è identico a Novus (NB100-1498). Scopri di più con meno.

1 Pubblicazioni

Clicca sull'immagine per la visualizzazione estesa

$480

Anticorpo policlonale di capra contro PAI1 per ELISA, WB e IHC.

Garanzia al 100%

Garanzia di corrispondenza del prezzo

Alternative Formats and ConjugatesAlternative Formats

Biotin

Consegna

Spese di spedizione

$40

Tempi di consegna

3-5 Giorni lavorativi

Contattaci

Telefono

+1 (314) 370-6046

E-mail

orders@antibodies.com

Garanzie

Garanzia di qualità al 100%

Garanzia di corrispondenza del prezzo

Descrizione Prodotto

Nome

Anti-PAI1 Antibody

Descrizione

Goat polyclonal antibody to PAI1.

Applicazioni

ELISA, WB, IHC

Diluizioni consigliate

ELISA: 1:64,000, WB: 0.1-0.3µg/ml, IHC: 4-6µg/ml

Reattività

Human

Immunogeno

Synthetic peptide corresponding to the internal region of human PAI1.

Sequenza

C-GFKIDDKGMAPALRH

Specie ospite

Goat

Clonalità

Polyclonal

Isotipo

IgG

Coniugare

Unconjugated

Purificazione

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Concentrazione

500 µg/ml

Peso molecolare

48 kDa

MW previsto

45.1kDa

Forma del prodotto

Liquid

Formulazione

Supplied in Tris Buffered Saline, pH 7.3, with 0.5% BSA and 0.02% Sodium Azide.

Conservazione

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze/thaw cycles.

Sinonimi

Clade E, Endothelial plasminogen activator inhibitor, Nexin, PAI, PAI 1, PAI-1, PAI1_HUMAN, PLANH1, Plasminogen activator inhibitor 1, Plasminogen activator inhibitor type 1, Serine (or cysteine) proteinase inhibitor, Serine (or cysteine) proteinase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1, Serpin E1, Serpin peptidase inhibitor clade E, Serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1, Serpine 1, SERPINE1

Controlli isotipo

Goat IgG (A121671)

Secondari adatti

Dichiarazione di non responsabilità

Questo prodotto è solo per uso di ricerca. Non è inteso per uso diagnostico o terapeutico.

Immagini (3)

Clicca sull'immagine per la visualizzazione estesa

Figure 1: Western Blot - Anti-PAI1 Antibody (A84079)

PAI1 expression in Human Liver lysate analyzed by western blot. Cells were lysed in RIPA buffer and 35µg protein was run per lane. Primary antibody incubation was performed with Anti-PAI1 Antibody (A84079) at 0.3µg/ml and detected by chemiluminescence.

Clicca sull'immagine per la visualizzazione estesa

Figure 2: Western Blot - Anti-PAI1 Antibody (A84079)

PAI1 expression in A549 (A), HepG2 (B) and HeLa (C) cell lysates analyzed by western blot. Cells were lysed in RIPA buffer and 35µg protein was run per lane. Primary antibody incubation was performed with Anti-PAI1 Antibody (A84079) at 0.1µg/ml and detected by chemiluminescence.

Clicca sull'immagine per la visualizzazione estesa

Figure 3: Immunohistochemistry - Anti-PAI1 Antibody (A84079)

PAI1 expression in Human Placenta analyzed by immunohistochemistry. Tissue was paraffin-embedded, and antigen retrieval was achieved by steaming in Tris/EDTA buffer, pH 9. Staining was performed with Anti-PAI1 Antibody (A84079) at 4µg/ml and revealed with horseradish peroxidase (HRP).

Pubblicazioni (1)

Visualizza pubblicazione

Cancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric aD pocket

Riferimenti: Anti-PAI1 Antibody (A84079)

Astratto:

Although the involvement of protein kinase CK2 in cancer is well-documented, there is a need for selective CK2 inhibitors suitable for investigating CK2 specific roles in cancer-related biological pathways and further exploring its therapeutic potential. Here, we report the discovery of AB668, an outstanding selective inhibitor that binds CK2 through a bivalent mode, interacting both at the ATP site and an allosteric aD pocket unique to CK2. Using caspase activation assay, live-cell imaging, and transcriptomic analysis, we have compared the effects of this bivalent inhibitor to representative ATP-competitive inhibitors, CX-4945, and SGC-CK2-1. Our results show that in contrast to CX-4945 or SGC-CK2-1, AB668, by targeting the CK2 aD pocket, has a distinct mechanism of action regarding its anti-cancer activity, inducing apoptotic cell death in several cancer cell lines and stimulating distinct biological pathways in renal cell carcinoma.

Visualizza pubblicazione